Cynosure, Inc. (CYNO)
-NasdaqGS 25.29 
0.25(1.00%) May 24, 4:00PM EDT
| Prev Close: | 25.04 |
|---|
| Open: | 24.81 |
|---|
| Bid: | 25.29 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 36.50 |
|---|
| Beta: | 1.44 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 24.59 - 25.50 |
|---|
| 52wk Range: | 18.37 - 30.20 |
|---|
| Volume: | 162,811 |
|---|
| Avg Vol (3m): | 193,264 |
|---|
| Market Cap: | 410.03M |
|---|
| P/E (ttm): | 33.02 |
|---|
| EPS (ttm): | 0.77 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Domino's and Cynosure Added to S&P Indicesat Motley Fool(Thu, May 23)
- Domino's Pizza to Join S&P MidCap 400; Cynosure to Join S&P SmallCap 600PR Newswire(Wed, May 22)
- Cynosure to replace NCI Building Systems in S&P 600 as of May 31theflyonthewall.com(Wed, May 22)
- Cynosure's CEO Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
- Cynosure Enters Oversold Territory (CYNO)at TheStreet(Mon, May 20)
- CYNOSURE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- Investing In Increased Tattoo Removal With Cynosureat Seeking Alpha(Thu, May 16)
- CYNOSURE INC FinancialsEDGAR Online Financials(Wed, May 15)
- This Hedge Fund Just Overhauled Its Equity Portfolio; Should You Pay Attention?at Seeking Alpha(Sun, May 12)
- CYNOSURE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Cramer: Buy Discover Financial, Allergan, and These 2 Stocks, But Sell Cynosureat Wall St. Cheat Sheet(Tue, May 7)
- Cynosure to Present at UBS Global Healthcare ConferencePR Newswire(Tue, May 7)
- [video] Lightning Roundat CNBC(Mon, May 6)
- Cynosure's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Cynosure Earnings: Here’s Why Investors Like These Resultsat Wall St. Cheat Sheet(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | 20.56 |
|---|
| P/S (ttm): | 2.54 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.74 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.18 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | 0.38 |
|---|
Business Summary
Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems primarily to the dermatology, plastic surgery, and general medical markets.
View More